This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, P. L. Articles by Katavatis, V. Search for Related Content PubMed PubMed Citation Articles by Thompson, P. L. Articles by Katavatis, V. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Heart Attack

Circulation, Vol 59, 113-119, Copyright © 1979 by American Heart Association

ARTICLES

Enzymatic indices of myocardial necrosis: influence on short- and long- term prognosis after myocardial infarction

PL Thompson, EE Fletcher and V Katavatis

The prognostic effect of the peak level of serum creatine kinase (CK) and aspartate transaminase (AST), estimated daily for 3--5 days after acute myocardial infarction, was studied in 560 patients who survived the first day in hospital. In a subgroup of 54 patients, peak enzyme levels correlated well with the cumulated CK release (r = 0.90 with peak CK, r = 0.74 with peak AST), thus reflecting the extent of myocardial necrosis. Total mortality within a year after infarction was not significantly different in the lower three quintiles of peak serum enzyme level, but increased from 15.5% to 27.9% (p less than 0.001) when peak CK level exceeded eight times the upper limit of normal (8 X N) and form 13.1% to 34.8% (p less than 0.001) when peak AST level exceeded five time the upper limit of normal (5 X N). The effect of high enzyme levels was more marked in patients with a prior history of myocardial infarction; mortality increased from 14.7% for first infarctions to 18.2% for recurrent infarctions, with peak CK greater than 8 X N, and from 27.0% for first infarctions to 38.0% for recurrent infarctions with peak CK greater than 8 X N. Early mortality was more significantly affected (p less than 0.0001) than late mortality (p less than 0.05). In hospital survivors, late deaths from cardiac decompensation were three times (p less than 0.05) more frequent in the high enzyme group as in the low enzyme group, but the number of sudden deaths was unaffected. These findings have important implications for studies of reduction of myocardial infarct size.

This article has been cited by other articles:

				A. Halkin, G. W. Stone, C. L. Grines, D. A. Cox, B. D. Rutherford, P. Esente, C. M. Meils, P. Albertsson, A. Farah, J. E. Tcheng, et al. Prognostic Implications of Creatine Kinase Elevation After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction J. Am. Coll. Cardiol., March 7, 2006; 47(5): 951 - 961. [Abstract] [Full Text] [PDF]

				P. Staat, G. Rioufol, C. Piot, Y. Cottin, T. T. Cung, I. L'Huillier, J.-F. Aupetit, E. Bonnefoy, G. Finet, X. Andre-Fouet, et al. Postconditioning the Human Heart Circulation, October 4, 2005; 112(14): 2143 - 2148. [Abstract] [Full Text] [PDF]

				L. K. Newby, B. U. Goldmann, and E. M. Ohman Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 31S - 36S. [Abstract] [Full Text] [PDF]

				U. Zeymer, H. Suryapranata, J. P. Monassier, G. Opolski, J. Davies, G. Rasmanis, G. Linssen, U. Tebbe, R. Schroder, R. Tiemann, et al. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction: Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1644 - 1650. [Abstract] [Full Text] [PDF]

				J. Hirsh and J. A. Cairns Analytic Reviews : Antithrombotic Tberapy in Acute Myocardial Infarction and Unstable Angina J Intensive Care Med, November 1, 1987; 2(6): 299 - 312. [PDF]